Vor Biopharma Stock News

Zacks Investment Research lowered shares of Vor Biopharma (NYSE:VOR) from a buy rating to a hold rating in a report published on Saturday morning, Zacks.com reports. According to Zacks, Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. [] The post Vor Biopharma (NYSE:VOR) Downgraded to Hold at Zacks Investment Research appeared first on ETF Daily News .

CAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Daniella Beckman to its board of directors. Ms. Beckman, who is currently the Chief Financial Officer of Tango Therapeutics and board member for Vor Biopharma

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vors President and Chief Executive Officer, will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit.

Nuveen Asset Management LLC raised its position in Vor Biopharma Inc. (NYSE:VOR) by 16.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,202 shares of the companys stock after purchasing an additional 6,675 shares during the quarter. Nuveen Asset Management LLC owned []

Charles Schwab Investment Management Inc. decreased its position in Vor Biopharma Inc. (NYSE:VOR) by 5.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 69,030 shares of the companys stock after selling 4,211 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.19% of []

CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vors President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual Healthcare Conference.

Shares of Vor Biopharma Inc. (NYSE:VOR) gapped down before the market opened on Wednesday . The stock had previously closed at $17.31, but opened at $16.06. Vor Biopharma shares last traded at $15.57, with a volume of 192 shares. Several equities analysts have issued reports on the company. JMP Securities assumed coverage on Vor Biopharma […]

The average of price targets set by Wall Street analysts indicates a potential upside of 186.2% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor's President and Chief Execut

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the upcoming presentation of new data from its no

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vor'

The FDA has granted Fast Track designation to Vor Biopharma's (NASDAQ: VOR) VOR33, lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for acute myeloid leukemia (AML). VOR33 cons